Ian Davis

Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate Cancer

Edmond M Kwan, Heidi Fettke, Maria M Docanto, Sarah Q To, Patricia Bukczynska, Andrew Mant, David Pook, Nicole Ng, Lisa-Jane K Graham, Stefano Mangiola, Eva Segelov, Kate Mahon, Ian D Davis, Phillip Parente, Carmel Pezaro, Tilman Todenhoefer, Lisa G Horvath, Arun A Azad

Journal article  |  2021  |  EUROPEAN UROLOGY FOCUS

BACKGROUND: The treatment paradigm for metastatic castration-resistant prostate cancer (mCRPC) has evolved significantly in recent..

Compliance with follow-up for patients with stage 1 testicular germ cell tumour

King Tung Cheung, Anthony Dat, Peter Wong, Caroline Dowling, Ian D Davis, Shomik Sengupta

Journal article  |  2021  |  ANZ JOURNAL OF SURGERY

BACKGROUND: This study aimed to evaluate the compliance and loss-to-follow-up (LTFU) rate in patients with stage 1 testicular germ..

Continuous Bladder Irrigation after Transurethral Resection of Non-Muscle Invasive Bladder Cancer for Prevention of Tumour Recurrence - A Systematic Review

M Li, J Toniolo, R Nandurkar, N Papa, N Lawrentschuk, ID Davis, S Sengupta

Conference Proceedings  |  2020  |  UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

TheraP: A randomised phase 2 trial of 177Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel - initial results (ANZUP protocol 1603).

Michael Hofman, Louise Emmett, Shahneen Sandhu, Amir Iravani, Anthony Joshua, Jeffrey Goh, David Pattison, Hsiang Tan, Ian Kirkwood, Siobhan Ng, Roslyn J Francis, Craig Gedye, Natalie Rutherford, Alison Y Zhang, Margaret McJannett, Martin Stockler, JOhn Violet, Scott Williams, Andrew Martin, Ian D Davis

Conference Proceedings  |  2020  |  ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY

Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial

Andrew Kneebone, Carol Fraser-Browne, Gillian M Duchesne, Richard Fisher, Mark Frydenberg, Alan Herschtal, Scott G Williams, Chris Brown, Warick Delprado, Annette Haworth, David J Joseph, Jarad M Martin, John HL Matthews, Jeremy L Millar, Mark Sidhom, Nigel Spry, Colin I Tang, Sandra Turner, Kirsty L Wiltshire, Henry H Woo, et al.

Journal article  |  2020  |  LANCET ONCOLOGY

Background: Adjuvant radiotherapy has been shown to halve the risk of biochemical progression for patients with high-risk disease ..

694TiP DASL-HiCaP: Darolutamide augments standard therapy for localised very high-risk cancer of the prostate (ANZUP1801). A randomised phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation

T Niazi, S Williams, ID Davis, MR Stockler, A Martin, K Bracken, F Roncolato, M McJannett, L Horvath, S Sengupta, S Hughes, R McDermott, J Catto, P Kelly, N Vapiwala, WR Parulekar, S Morgan, RA Rendon, C Sweeney

Conference Proceedings  |  2020  |  Annals of Oncology

Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome-Results from the International Metastatic Renal Cell Carcinoma Database Consortium

Frede Donskov, Wanling Xie, Anders Overby, J Connor Wells, Anna P Fraccon, Cosimo S Sacco, Camillo Porta, Igor Stukalin, Jae-Lyun Lee, Konstantinos Koutsoukos, Takeshi Yuasa, Ian D Davis, Carmel Pezaro, Ravindran Kanesvaran, Georg A Bjarnason, Hao-Wen Sim, Nityam Rathi, Christian K Kollmannsberger, Christina M Canil, Toni K Choueiri, et al.

Journal article  |  2020  |  EUROPEAN UROLOGY ONCOLOGY

BACKGROUND: Patients with metastatic renal cell carcinoma (mRCC) may present with primary metastases (synchronous disease) or deve..

Nursing Implications of Recent Changes in Management Practices for Metastatic Prostate Cancer.

Caitlin Bennett, Ian D Davis, Anis A Hamid

Journal article  |  2020  |  Semin Oncol Nurs

OBJECTIVE: Prostate cancer is one of the most common male cancers in the world and accounts for substantial morbidity, mortality, ..

Prognostic Impact of Total Plasma Cell-free DNA Concentration in Androgen Receptor Pathway Inhibitor-treated Metastatic Castration-resistant Prostate Cancer.

Heidi Fettke, Edmond M Kwan, Patricia Bukczynska, Nicole Ng, Tu Nguyen-Dumont, Melissa C Southey, Ian D Davis, Andrew Mant, Phillip Parente, Carmel Pezaro, Christine Hauser, Arun A Azad

Journal article  |  2020  |  Eur Urol Focus

Total plasma cell-free DNA (cfDNA) levels were recently shown to be prognostic in two large phase III trials of taxane chemotherap..

TheraP: A randomised phase II trial of Lu-177-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: Initial results (ANZUP protocol 1603).

Michael S Hofman, Louise Emmett, Shahneen Kaur Sandhu, Amir Iravani, Anthony M Joshua, Jeffrey C Goh, David A Pattison, Thean Hsiang Tan, Ian D Kirkwood, Siobhan Ng, Roslyn J Francis, Craig Gedye, Natalie K Rutherford, Alison Yan Zhang, Margaret Mary McJannett, Martin R Stockler, John A Violet, Scott Williams, Andrew James Martin, Ian D Davis

Conference Proceedings  |  2020  |  JOURNAL OF CLINICAL ONCOLOGY

5500 Background: LuPSMA is a radiolabeled small molecule that delivers therapeutic β-radiation to PSMA-expressing tumors. Encoura..